These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 16480268

  • 1. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM, Lawrence HR, Cornet J, Bubert C, Fischer DS, Vicker N, Smith A, Tutill HJ, Purohit A, Day JM, Mahon MF, Reed MJ, Potter BV.
    J Med Chem; 2006 Feb 23; 49(4):1325-45. PubMed ID: 16480268
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
    Laplante Y, Cadot C, Fournier MA, Poirier D.
    Bioorg Med Chem; 2008 Feb 15; 16(4):1849-60. PubMed ID: 18035543
    [Abstract] [Full Text] [Related]

  • 4. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Vicker N, Lawrence HR, Allan GM, Bubert C, Smith A, Tutill HJ, Purohit A, Day JM, Mahon MF, Reed MJ, Potter BV.
    ChemMedChem; 2006 Apr 15; 1(4):464-81. PubMed ID: 16892382
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S, Alho-Richmond S, Wahala K.
    Mol Cell Endocrinol; 2009 Mar 25; 301(1-2):225-8. PubMed ID: 18822344
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
    Möller G, Deluca D, Gege C, Rosinus A, Kowalik D, Peters O, Droescher P, Elger W, Adamski J, Hillisch A.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6740-4. PubMed ID: 19836949
    [Abstract] [Full Text] [Related]

  • 9. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
    Mazumdar M, Fournier D, Zhu DW, Cadot C, Poirier D, Lin SX.
    Biochem J; 2009 Dec 10; 424(3):357-66. PubMed ID: 19929851
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Bey E, Marchais-Oberwinkler S, Kruchten P, Frotscher M, Werth R, Oster A, Algül O, Neugebauer A, Hartmann RW.
    Bioorg Med Chem; 2008 Jun 15; 16(12):6423-35. PubMed ID: 18514529
    [Abstract] [Full Text] [Related]

  • 11. Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM, Bubert C, Vicker N, Smith A, Tutill HJ, Purohit A, Reed MJ, Potter BV.
    Mol Cell Endocrinol; 2006 Mar 27; 248(1-2):204-7. PubMed ID: 16337736
    [Abstract] [Full Text] [Related]

  • 12. E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Fischer DS, Allan GM, Bubert C, Vicker N, Smith A, Tutill HJ, Purohit A, Wood L, Packham G, Mahon MF, Reed MJ, Potter BV.
    J Med Chem; 2005 Sep 08; 48(18):5749-70. PubMed ID: 16134943
    [Abstract] [Full Text] [Related]

  • 13. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A, Bhoga U, Bey E, Müller-Vieira U, Messinger J, Thole H, Hartmann RW.
    J Med Chem; 2008 Aug 14; 51(15):4685-98. PubMed ID: 18630892
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A, Klein T, Werth R, Kruchten P, Bey E, Negri M, Marchais-Oberwinkler S, Frotscher M, Hartmann RW.
    Bioorg Med Chem; 2010 May 15; 18(10):3494-505. PubMed ID: 20413314
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
    Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM, Fischer DS, Vicker N, Newman SP, Potter BV, Reed MJ.
    Mol Cell Endocrinol; 2006 Mar 27; 248(1-2):199-203. PubMed ID: 16414180
    [Abstract] [Full Text] [Related]

  • 18. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.
    Karkola S, Lilienkampf A, Wähälä K.
    ChemMedChem; 2008 Mar 27; 3(3):461-72. PubMed ID: 18224704
    [Abstract] [Full Text] [Related]

  • 19. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity.
    Chetrite GS, Thole HH, Philippe JC, Pasqualini JR.
    Anticancer Res; 2004 Mar 27; 24(3a):1433-8. PubMed ID: 15274306
    [Abstract] [Full Text] [Related]

  • 20. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
    Day JM, Tutill HJ, Foster PA, Bailey HV, Heaton WB, Sharland CM, Vicker N, Potter BV, Purohit A, Reed MJ.
    Mol Cell Endocrinol; 2009 Mar 25; 301(1-2):251-8. PubMed ID: 18786604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.